ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

LNF2007

A development code.

Its studies are led by Lunan Pharmaceutical Group.

Furthest: phase 1, since Dec 22, 20241 company-led study, 1 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lunan Pharmaceutical Group11 open or runningphase 1since Dec 22, 2024Dec 22, 2024Dec 2026phase 1 · NCT06752447

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2024First study: phase 1 study in Advanced Solid Tumors (Phase 1)First studyNCT06752447 · 94 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in Advanced Solid Tumors (Phase 1)NCT06752447

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06752447Advanced Solid Tumors (Phase 1)1Not yet recruitingDec 202694

How it is read

Names in the registry

  • “LNF2007”, 1 entry

Codes read as this program: LNF2007.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.